SYDNEY, AUSTRALIA and LONDON and NEW CANAAN, CT--(Marketwire - March 10, 2008) - The role of the investigational drug phenoxodiol in restoration of chemosensitivity in ovarian cancer patients resistant to platinum drugs was the subject of a keynote address at the Ovarian Cancer Action International Conference, held in London on Saturday.
